The causes of autoimmune diseases are complex. Stimulated by specific antigens, the immune system will be repeatedly or excessively activated, resulting in increased cytokine secretion, mediated immune response attacking normal tissues, or callus formation through compensatory pathways, thus impairing normal physiological functions.

Relying on our own antibody discovery and drug evaluation platform, we have developed highly-effective blocking antibodies for different types of autoimmune diseases to effectively reduce effector cell- and cytokine-mediated inflammatory responses, and then to influence the disease progress and to improve the quality of life in patients.

The treatment of malignant tumors has significantly developed  in recent years, especially the continuous breakthroughs in cancer immunotherapy. To further improve the clinical benefits for more patients and develop more effective treatment methods, we have cooperated with top domestic academic institutions and well-known companies in the industry to identify new targets, new mechanisms of action, and new combinations. At present, multiple molecules are in different stages of drug development.